Pfizer (NYSE:PFE) shares rise 3.6% on dividend strength as analyst forecasts remain unchanged
Pfizer Inc. rose 3.6% last week, outperforming the S&P 500 by 5.2 percentage points. Shares finished Friday at $25.05.
TrumpRx’s 800-Drug List Masks Modest Pharma Price Exposure
TrumpRx currently includes around 10% of the branded drug portfolios offered by pharmaceutical companies taking part in the program, well below the widely cited figure of more than 800 medicines.
Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue
Pfizer Inc. shares rose 2.35% to $24.82 on Wednesday after Sanofi SA brought a new patent case over the Comirnaty COVID-19 vaccine. The gain suggests investors viewed the complaint as a possible charge against past vaccine earnings, rather than an immediate block on sales.
Pfizer (NYSE:PFE) Holds 7% Yield as AI Selloff Hits, Options Traders Look for Protection
Pfizer added 1.28% to $24.48 in post-market trading Monday. The stock outperformed the broader market and two other major pharma names while investors moved out of risk on worries about rising U.S.-Iran tensions, higher oil, and chip stocks selling off. The NYSE closed the regular session at 4 p.m. EDT, but after-hours trading was still open when this was published.
Pfizer (NYSE:PFE) scores FDA approval but Wall Street reaction muted
U.S. markets are shut for the weekend, so investors are waiting to see if Friday’s FDA approval of Padcev with Keytruda will do much for Pfizer Inc.’s earnings. So far, no big move. Pfizer slipped 0.33% to $24.17 on Friday, down 0.62% since the July 2 close before the July 4 break. The S&P 500 rose 1.2% last week. The FDA cleared the drug based on a 47% lower risk of recurrence, progression or death, which looks strong clinically. But investors want more proof that sales to bladder-cancer patients can make up for Pfizer’s patent losses.
Pfizer rebound keeps dividend stable, HSBC lowers upside by $23 billion
Pfizer Inc. traded up 1.7% at $24.13 as of 11:48 a.m. EDT Tuesday, recovering some ground after Monday’s 2.47% slide to $23.72. The stock’s loss on Monday stood out with the S&P 500 up 0.72% and the Dow up 0.29%, making it a clear underperformer, not just a victim of the broader market.
Pfizer (NYSE:PFE) stock selloff turns HSBC downgrade into dividend-cover test
Pfizer Inc fell in Monday morning trade after HSBC Holdings cut its rating, but the sharper investor question is now dividend cover, not only the downgrade. The stock traded at $23.665 at 10:53 a.m. EDT, down about 2.7%, giving Pfizer a market value of about $135.6 billion.
Pfizer (NYSE:PFE) trades near 7% yield as pharma stocks stay soft, options imply calm
Pfizer Inc. heads into the long U.S. holiday weekend trailing the broad Big Pharma bounce this week. Shares added 1.84% to close at $24.32 on Thursday. The S&P 500 Index held nearly flat at 7,483.24, while the Dow climbed 1.14% to 52,900.07. NYSE trading is shut Friday with July 3 on the exchange’s holiday calendar as the 2026 Independence Day observed.
Pfizer (NYSE:PFE) gains with 7% yield as China trial faces questions
Pfizer Inc. moved higher late Thursday, but there was too much noise in the market to call the move a clear Pfizer recovery. Shares traded at $24.37, up 2.1% for the day. The Health Care Select Sector SPDR Fund climbed 2.3%. SPY fell 0.3%. Pfizer beat SPY, but couldn't top the sector's gain.
Pfizer (NYSE:PFE) yield tops 7% after stock falls on China GLP-1 news
Pfizer Inc traded lower Tuesday afternoon, trailing the main indexes again and raising fresh questions around the stock’s dividend. The New York Stock Exchange was open for normal trading hours. Its 2026 holiday calendar lists July 3 as the next full-day closure for Independence Day.
Pfizer (NYSE:PFE) trails S&P 500 as China GLP-1 watch puts yield in focus
Pfizer Inc. ticked up on Monday, rising after a move in China increased reimbursement for its GLP-1 offering, giving it another inroad into the market. Shares added 0.4% to $24.37 late in New York trading, but trailed a broader rally. The S&P 500 ended up 1.18% at 7,440.43, and the Nasdaq Composite jumped 2.07%.
Pfizer (NYSE:PFE) yield math back in focus after cancer drug miss, shares recover Friday
U.S. cash stock trading was closed Sunday. The New York Stock Exchange posts regular hours of 9:30 a.m. to 4:00 p.m. ET, and says its next holiday for 2026 is Independence Day, observed Friday, July 3. Pfizer’s last trade was Friday’s close.
Pfizer (NYSE:PFE): 7% yield in focus after FDA clears Ibrance but stock action mixed
Pfizer Inc. opens Thursday carrying a clearer income pitch, but growth looks shaky. Shares have slid, sending the dividend yield above 7%. The company scored an FDA win for Ibrance, its established breast cancer drug. But sigvotatug vedotin, a lung cancer antibody-drug conjugate from the Seagen deal, failed in late-stage testing.
Pfizer (NYSE:PFE) churns as investors price in bigger cancer pipeline discount after Seagen drug miss
Pfizer traded near flat in early premarket hours on Wednesday after a round of heavy selling that didn’t move the price much. Shares were at $24.76 at 7:07 a.m. EDT, just 0.16% higher than Tuesday’s $24.72 close. The stock is down about 14% from its 52-week high and up around 7% from its low.
Pfizer Shares Fall After Lung-Cancer Setback Hits $43 Billion Seagen Deal
Pfizer Inc. shares fell on Tuesday. The company said a key lung cancer drug from its Seagen unit didn’t hit the main endpoint in a late-stage study. That’s another setback for Pfizer as it tries to spark growth again after its COVID-era products.
Pfizer (NYSE:PFE) stock pinned near CFO-exit selloff as investors wait for proof on growth
Pfizer Inc entered Monday pinned near last week’s selloff, with investors still weighing the planned departure of finance chief Dave Denton against the company’s promise of post-2028 growth.
Pfizer starts week on the back foot after CFO leaves, outlook for 2026 still stands
Pfizer Inc. shares slid again after its CFO said he’ll step down in August. The stock closed at $25.21, losing 2.7% on Thursday before the Juneteenth holiday and the weekend.
Pfizer shares dip after CFO departure raises new questions about 2026 outlook
Pfizer dropped 2.7% to $25.21 Thursday, closing out a short week lower after its CFO said he is leaving. The news raised questions about Pfizer’s 2026 outlook and its post-pandemic turnaround. U.S. markets shut Friday for Juneteenth.
Pfizer Stock Falls as CFO Dave Denton Exit Revives Questions on Growth Plan
Pfizer shares dropped on Thursday after the drugmaker said finance chief Dave Denton would leave in August, a management change that hit a stock already being judged on a long and expensive growth rebuild.
Pfizer trades up with Rigel’s Veppanu deal done
Pfizer Inc. shares ticked up Tuesday after Rigel Pharmaceuticals announced it has finalized a licensing deal for Veppanu, the breast-cancer treatment Arvinas and Pfizer developed together. The move offered a small bit of news in cancer drugs for investors. Broader U.S. indexes finished the session mixed.